BioElectronics Corporation develops and markets drug-free anti-inflammatory patches. The company’s products include ActiPatch Therapy, a dermal drug-free, painless, and pulsed energy patch with an embedded battery operated microchip that delivers pulsed electromagnetic frequency therapies to accelerate healing of soft tissue injuries. Its technology provides pulsed electromagnetic energy therapy that is used to reduce swelling, relieve pain, and enhance the healing of post-surgical incisions, chronic wounds, and orthopedic conditions. The company markets its products in the United States, Canada, and Europe. BioElectronics Corporation sells its products to wholesale distributors, as well as directly to hospitals and clinics. Recent Highlights

• BioElectronics has retained industry leader, Schulberg MediaWorks as its marketing partner. Work on the DRTV spots has already begun with initial airing expected within 60 days. Initially, the Canadian and selected other English speaking markets will be targeted, but the U.S. market will also be heavily targeted once FDA clearance is received.

• Indendent analyst Carrie Snyder, places a target price on BIEL shares of between $0.30 and $0.50, should expected FDA clearances be granted.

• Clinical Results — David G. Genecov, M.D. FACS FAAP, provided preliminary data on a heel and foot pain study showing strong efficacy and 100% safety using the ActiPatch device. The study also showed study participants were able to significantly reduce their use of acetaminophen, the active ingredient in Tylenol, and non-steroidal anti-inflammatory drugs (NSAIDs). Considering the recent FDA panel recommendation relating to acetaminophen usage, these results are highly significant.

• Clinical Studies and FDA Filings — Clinical studies in the areas of breast augmentation, Cesarean section, Uveitis, and several areas of surgical recovery are quickly coming to a close with data expected over the coming months. With the data provided by the Genecov study, the management team plans to accelerate its FDA 510(k) pre-marketing clearance filing for general musculoskeletal complaints designed to lead to over-the-counter approval. In addition, the Company will soon submit an additional application of 510(k) pre-marketing clearance for general surgical recovery.

• International Distribution Expansion — International distribution relationships continue to advance at a rapid rate. The Company announced it will soon be entering the German and Spanish markets, which will augment other international markets, particularly the Italian, Korean and Canadian markets, which are already showing revenue acceleration. Several Asian distribution partnership agreements are currently being negotiated.

• Financials — Management indicated that the financial position of the Company has improved dramatically over the past few months. Further payments have been made on convertible debentures with balances dropping from more than $910,000 one year ago to less than $50,000 today. Elimination of all convertible debenture balances is likely over the coming weeks. BioElectronics is maintaining very strong gross margins and tight expense controls, resulting in the Company operating at near breakeven levels. The working capital position at the Company has also significantly improved. The recent U.S. Government Export-Import Bank guarantee is expected to further improve the working capital position.

• Company Priorities — The priorities for BioElectronics remain the completion of clinical trials, FDA submissions, expansion of international distribution, and the further development of our patented, drug-free brands: Allay, ActiPatch and RecoveryRx.

• BioElectronics Receives Groundbreaking Patent – PEMF technology has been proven safe and effective in hundreds of peer-reviewed scientific studies. Up until now, however, PEMF devices have been very expensive large devices and usually based in clinical settings such as clinics or hospitals. Through the use of advanced micro-circuitry the engineers at BioElectronics have shrunk this technology into a wafer-thin device that can be worn directly on the skin to relieve pain, swelling and speed healing.

Why this is a hot stock

- BioElectronics Announces Worldwide DRTV Strategy to Launch DRTV Campaigns in South America, Canada and Europe.

- BioElectronics Technology More Effective Than Extra Strength Tylenol(R) in Reducing Muscle Soreness. In Clinical Study ActiPatch Proved 50 Percent More Effective Than Acetaminophen.

- Monday October 19, 2009 BioElectronics Corp. announced the initial results from the pilot section of its ongoing acetaminophen comparison study. The study, which is expected to be complete during early November, compares the effects of ActiPatch? Therapy to acetaminophen in the form of Extra Strength Tylenol? for the treatment of delayed onset muscle soreness (DOMS).

- Wednesday September 30, 2009 BioElectronics Corp. announced the availability of a new product targeted at the $10 billion dollar veterinary care market, the HealFast Therapy PetPatch(TM).

- Biel is waiting on FDA approval for its Allay Patch anticipated 2nd half of August while planning on filing 2 more FDA 510k submissions. Per last conference call on July 28th, 2009 , 2 institutional investors have invested in Biel which is very rare and a real honor for companies traded on the Pink Sheets.

BioElectronics Corporation
4539 Metropolitan City
Frederick, MD 21704
Phone: 301-644-3906
Fax: 301-644-3937
www.bielcorp.com